Establishment of serum Heparanase concentration measurement method and its application to gynecologic cancer treatment

血清乙酰肝素酶浓度测定方法的建立及其在妇科肿瘤治疗中的应用

• 批准号: 20591955
• 负责人: AOKI Yoichi
• 金额: $ 3万
• 依托单位: University of the Ryukyus
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2008
• 资助国家: 日本
• 起止时间: 2008 至 2010
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-20591955/
• 关键词: ヘパラナーゼ; 抗ヘパラナーゼ抗体; 血清ヘパラナーゼ値; 婦人科癌; 転移抑制療法; ELISA; 血清中ヘパラナーゼ値; 婦人科がん患者; 担癌患者

To establish a measurement method of serum heparanase titer, we constructed ELISA system using antiHPR1 antibody, synthesized peptide for heparanase, and biotin-labeled peptide. The ELISA for heparanase measurement worked well in the reaction of the antibody and the synthesized peptide between concentrations of 10 to 1,000 nmol/l of HPR1 peptide. The ELISA also worked well in the measurement of serum heparanase between concentrations of 1 to 100nmol/l of HPR1 peptide. We tried to measure the 22 serum samples from patients with cervical cancer, endometrial cancer and ovarian cancer, and were able to get appropriate titers of heparanase concentration in each sample. These data indicate that our ELISA system for the measurement of serum heparanase titer is applicable for a clinical setting.

为了建立血清乙酰肝素酶效价的测定方法，我们使用抗HPR 1抗体、合成的乙酰肝素酶肽和生物素标记肽构建了ELISA体系。肝素酶测定用ELISA在HPR 1肽的浓度为10 ~ 1，000 nmol/l时，抗体与合成肽的反应良好。ELISA在HPR 1肽浓度为1 ~ 100 nmol/l范围内对血清乙酰肝素酶的测定效果良好。我们尝试测定22例宫颈癌、子宫内膜癌和卵巢癌患者的血清样本，并能够在每个样本中获得合适的乙酰肝素酶浓度滴度。这些数据表明，我们的ELISA系统的血清乙酰肝素酶滴度的测量是适用于临床设置。

项目成果

Recurrent juvenile granulosa cell tumor of the ovary managed by palliative radiotherapy

姑息性放疗治疗复发性幼年性卵巢颗粒细胞瘤

• 发表时间: 2007
• 期刊: International Journal of Gynecologic Cancer
• 作者: M. Hirakawa;Y. Nagai;C. Yagi;T. Nashiro;M. Inamine;Y. Aoki
• 通讯作者: Y. Aoki

Concomitant postoperative radiation and chemotherapy following surgery was associated with improved overall survival in patients with FIGO stage III and IV endometrial cancer.

手术后同时进行术后放疗和化疗与FIGO III 期和IV 期子宫内膜癌患者的总生存期改善相关。

• 发表时间: 2010
• 期刊: Int J Clin Oncol 15
• 作者: Nakayama K;Nagai Y;Ishikawa M;Aoki Y;Miyazaki K.
• 通讯作者: Miyazaki K.

Impressive 3 cases we enrolled in phase III study of S-1+cisplatin combination chemotherapy acompared with single agent cisplatin in stage IVB, recurrent, or persistent carcinoma of the cervix.

令人印象深刻的是，我们参加了 S-1 顺铂联合化疗与单药顺铂治疗 IVB 期、复发性或持续性宫颈癌的 III 期研究，令人印象深刻。

• 发表时间: 2009
• 作者: Kudaka W;Hirakawa M;Inamine M;Nagai Y;Aoki Y.
• 通讯作者: Aoki Y.

Risk factors for tumor recurrence in patients with stage III-IVA squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy.

同期放化疗的 III-IVA 期宫颈鳞状细胞癌患者肿瘤复发的危险因素。

• 发表时间: 2010
• 作者: Asato K.;Nagai Y;Oyakawa M;Nitta H;Okubo E;Hirakawa M;Kudaka W;Inamine M;Toita T;Aoki Y.
• 通讯作者: Aoki Y.

High-risk group for locoregional recurrence in patients with stage IB-IIB squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy.

• DOI: 10.1200/jco.2010.28.15_suppl.e15519
• 发表时间: 2010-05
• 期刊: Anticancer research
• 影响因子: 2
• 作者: M. Hirakawa;Y. Nagai;T. Toita;W. Kudaka;M. Inamine;K. Ogawa;S. Murayama;Y. Aoki